Colorectal cancer is one of the most common malignancies, with 1 million new cases and half a million deaths each year worldwide [1]. The development of metastases is the main cause of death. Liver metastases are diagnosed in 10–25% of patients at the time of resection of their primary colorectal tumor and, eventually, up to 70% of patients with colorectal cancer develop liver metastases [2, 3]. Without treatment, life expectancy for patients with colorectal metastases is poor and ranges from 5 to 9 months [4–6]. When the metastases are confined to the liver, which is the case in 30% of the patients [7], there are several locoregional treatment options, including partial hepatic resection, local ablative therapy, administration of chemotherapy by hepatic artery infusion, systemic chemotherapy and isolated hepatic perfusion (IHP) with high-dose chemotherapy. If patients are ineligible for locoregional treatment, systemic chemotherapy is the only treatment option for metastatic colorectal cancer.